Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8710890 | Annales de Dermatologie et de Vénéréologie | 2018 | 6 Pages |
Abstract
Even if cutaneous CD30+ lymphoproliferative disorders occur only rarely during fingolimod treatment, dermatologists should nevertheless be aware of this association for which strict dermatological surveillance is required. We would also stress that these CD30+ lymphoproliferative disorders can disappear spontaneously, as in our case, even if treatment by fingolimod is continued.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
E. Cesbron, J.-B. Monfort, C. Giannesini, P. Duriez, P. Moguelet, P. Senet, C. Francès, A. Barbaud, F. Chasset,